Cover Image


Investigation Report on China Pregabalin Market, 2009-2018

出版商 China Research and Intelligence 商品編碼 297272
出版日期 內容資訊 英文 40 Pages
商品交期: 最快1-2個工作天內
Back to Top
中國的Pregabalin市場分析 Investigation Report on China Pregabalin Market, 2009-2018
出版日期: 2014年03月06日 內容資訊: 英文 40 Pages



第1章 Pregabalin的相關概念

  • 適應
  • 全球市場銷售情形

第2章 中國的Pregabalin的市場概要

  • 對中國的流程
  • 主要製造商
  • 專利狀況
  • 市場規模

第3章 中國的Pregabalin的銷售額分析

  • 整體銷售額
  • 銷售額:各地區

第4章 中國的Pregabalin的主要廠商的市場佔有率分析

第5章 中國的Pregabalin(各劑型)的市場規模分析

第6章 中國的醫院市場上Pregabalin的標準價格

第7章 中國的Pregabalin市場上主要製造商

  • Pfizer Deutschland GmbH
  • Chongqing Succeway Pharmaceutical Co., Ltd.

第8章 中國的Pregabalin市場預測

  • 中國的癲癇發病率趨勢
  • 學名藥狀況
  • 市場規模的預測
  • 競爭格局的預測


Product Code: 1403127

Neuropathic pain is caused by damage or pathological changes of nervous system. Its main features are dull pain, aestus and tingling. About 1% of people worldwide have neuropathic pain. Epileptic seizures are the result of excessive and abnormal cortical nerve cell activity in the brain. It is a group of long-term neurological disorders. As a chronic disease, epilepsy can seriously damage patients' mental and physical health and become a huge burden for their families and the society. According to WHO, the global number of epilepsy patients is higher than 50 million and over 9 million of them are in China.

Pfizer Co., Ltd. submitted registration application for Pregabalin (produced by Pfizer with the trade name "Lyrica") in the U.S. in 2003. In December 2004 pregabalin was approved by FDA to treat diabetic neuropathic pain and postherpetic neuralgia. It is the first drug approved to treat both the two diseases in the U.S.A. and in Europe. In June 2005, pregabalin was approved to be used in the adjuvant treatment of adults with partial-onset seizures in epilepsy. After that, it was approved to treat generalized anxiety disorder and fibromyalgia syndrome successively. Time Magazine named pregabalin as one of the "Top 10 Medical Progress" in 2007. Total revenue of pregabalin is more than USD 20 billion. The global sales revenue of Lyrica was approximately USD 4.16 billion, increased by 13% YOY.

In 2010 Lyrica was approved to China. According to CRI's market investigation, the sales revenue of Lyrica in Chinese sample hospital market grew over 100 times from 2010 to 2013. Due to Lyrica's success, many pharmaceutical manufacturers in China begin to apply for pregabalin production. Chongqing Succeway Pharmaceutical Co., Ltd. received production license in 2013. Lyrica produced by Pfizer is expected to be the main product in Chinese market in recent years. However, its market share will decline in 2014 due to competition from relatively cheap homemade drugs.

Based on its development in the past, incidence of epilepsy is doomed to increase, which leads to a bright future for pregabalin market in China.

Through this report, the readers can acquire the following information:

  • Sales price of Pregabalin in Hospital Market in China
  • Major Pregabalin Manufacturers in China
  • Patent Status of Pregabalin in China
  • Share of Pregabalin in Different Dosage Forms in China Hospital Market

The following enterprises and people are recommended to purchase this report:

  • Antiepileptic Drug Manufacturers
  • Investors /Research Agencies Focusing on Nervous System Drug Market

Table of Contents

1. Relevant Concepts of Pregabalin

  • 1.1. Development Process and Indication
  • 1.2. Sales Status on the Global Market

2. Market Overview of Pregabalin in China, 2010-2013

  • 2.1. Process of Pregabalin into China
  • 2.2. Major Manufacturers
  • 2.3. Patent Status
  • 2.4. Investigation on Market Size

3. Investigation on Sales Value of Pregabalin in China, 2010-2013

  • 3.1. Total Sales Value
  • 3.2. Sales Value by Region

4. Investigation on Market Share of Major Pregabalin Manufacturers in China, 2010-2013

5. Investigation on Market Size of Pregabalin by Dosage Form in China, 2010-2013

6. Reference Price Pregabalin in China Hospital Market, 2014

7. Major Manufacturing Enterprises in China Pregabalin Market, 2010-2014

  • 7.1. Pfizer Deutschland GmbH
  • 7.2. Chongqing Succeway Pharmaceutical Co., Ltd.

8. Prospect of China Pregabalin Market, 2014-2018

  • 8.1. Trend of Epilepsy Incidence in China
  • 8.2. Status of Generic Drug
  • 8.3. Forecast on Market Size
  • 8.4. Forecast on Competition Pattern

Selected Charts

  • Chart Pregabalin Products Approved to Market in China by 2014
  • Chart Sales Value of Pregabalin in Global Market, 2009-2013
  • Chart Pregabalin Products Approved in China Market
  • Chart Patent Status of Pregabalin in China
  • Chart Sales Value of Pregabalin in Hospital Market in China, 2009-2013
  • Chart Sales Value of Pregabalin by Region in China, 2009-2013
  • Chart Market Share of Pregabalin Enterprises by Sales Value in China, 2009-2013
  • Chart Price of Pregabalin Produced by Pfizer Deutschland GmbH in China Hospital Market, 2014
  • Chart Forecast on Market Size of Hospital-use Pregabalin in China, 2014-2018
Back to Top